Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:GMTXNASDAQ:NAMSNASDAQ:OPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$26.48+3.6%$22.07$16.50▼$26.55$2.31BN/A62,291 shs19,849 shsGMTXGemini Therapeutics$48.04-1.7%$45.86$1.16▼$14.10$2.08B-0.12189,291 shs216,877 shsNAMSNewAmsterdam Pharma$17.61-3.7%$18.58$14.06▼$27.29$1.93B0.01637,089 shs274,673 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$524.84M1.1226,751 shs3,000 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+3.60%+16.91%+10.79%+25.08%+2,647,999,900.00%GMTXGemini Therapeutics-1.74%+2.02%+9.16%-11.61%+53.68%NAMSNewAmsterdam Pharma-3.67%-6.73%+1.97%-5.17%-10.06%OPTOpthea0.00%0.00%0.00%-32.07%+4.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma2.6497 of 5 stars3.51.00.00.02.95.00.0OPTOpthea0.6802 of 5 stars2.10.00.00.01.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AGMTXGemini Therapeutics 0.00N/AN/AN/ANAMSNewAmsterdam Pharma 3.00Buy$43.00144.18% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideCurrent Analyst Ratings BreakdownLatest OPT, NAMS, GMTX, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.002/28/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/27/2025NAMSNewAmsterdam PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.35N/AN/AN/A∞GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ANAMSNewAmsterdam Pharma$47.14M41.02N/AN/A$3.50 per share5.03OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ANAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ALatest OPT, NAMS, GMTX, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AGMTXGemini TherapeuticsN/A71.4971.49NAMSNewAmsterdam PharmaN/A10.6110.61OPTOptheaN/A2.942.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AGMTXGemini Therapeutics75.42%NAMSNewAmsterdam Pharma89.89%OPTOpthea55.95%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AGMTXGemini Therapeutics12.90%NAMSNewAmsterdam Pharma20.84%OPTOpthea3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableOPT, NAMS, GMTX, and AAPG HeadlinesRecent News About These CompaniesOpthea Limited (NASDAQ:OPT) Given Average Rating of "Hold" by AnalystsMay 17, 2025 | marketbeat.comHsbc Holdings PLC Makes New Investment in Opthea Limited (NASDAQ:OPT)May 9, 2025 | marketbeat.comBiotech Dimerix lands $940m licensing deal for kidney drug salesMay 1, 2025 | afr.comPhil King’s Regal successfully bets against Tesla, NvidiaMay 1, 2025 | afr.com'No one is happy': Regal stockpickers face financial hit after Opthea blow upApril 21, 2025 | capitalbrief.comRegal’s King says his hedge funds will recover from March madnessApril 16, 2025 | afr.comRegal: Don’t catch the falling knife, wait for it to stick in the floorApril 16, 2025 | msn.comOpthea to lay off approximately 65% of companyApril 10, 2025 | ophthalmologytimes.comOpthea lays off 65% of staff after back-to-back phase 3 eye disease flopsApril 10, 2025 | fiercebiotech.comBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comLifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugMarch 31, 2025 | endpts.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 failMarch 31, 2025 | fiercebiotech.comOpthea discontinues development of sozinibercept in wet AMDMarch 31, 2025 | healio.comOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 31, 2025 | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodHere's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryOPT, NAMS, GMTX, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$26.48 +0.92 (+3.60%) As of 05/23/2025 03:59 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Gemini Therapeutics NASDAQ:GMTX$48.04 -0.85 (-1.74%) As of 05/22/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$17.61 -0.67 (-3.67%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.34 +0.73 (+4.12%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 05/22/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
